BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Biostock PHI one year CEO anniversary

February 21, 2024

BioStock: PHI “We aim to revolutionize the regenerative medicine market“

BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.

BioStock-PHI-CEO-reflects-on-the-company-momentum

November 14, 2023

BioStock: PHI’s CEO reflects on the Company’s momentum

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.

Biostock-Altium-fuels-PHIs-forward-drive

November 9, 2023

BioStock: Altium fuels PHI’s forward drive

BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.

Businesspeople brainstorming together with sticky notes in an of

September 7, 2023

BioStock: PHI links up with two regenerative medicine networks

BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.

1…3 456 7…10